Eli Lilly and Company
893 S Delaware St
Indianapolis
Indiana
46285
United States
Tel: 317-276-2000
Website: http://www.lilly.com/
About Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to make life better for people around the world. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of disease, and giving back to communities through philanthropy and volunteerism. We also have been committed to investing in our employees – through competitive salaries, training and development, health, and the opportunity to do good. The pharmaceutical industry is a complex, rapidly changing environment and we’re looking for people who are determined to make life better for people around the world. Visit https://careers.lilly.com for more information.
Stock Symbol: LLY
Stock Exchange: NYSE
We discover life-changing medicines. We commit to diversity and inclusion. We volunteer millions of hours. We make life better. We are Lilly.
2188 articles with Eli Lilly and Company
-
Results from Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint in People with Type 1 and Type 2 Diabetes
10/2/2018
Both studies also showed greater reductions in glucose excursions after mealtime
-
Thomson Reuters recently announced their list of the top 100 most diverse and inclusive organizations. In the top 50 of the list there are 10 biopharma and medical device companies. Let’s take a look.
-
Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.).
-
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
-
The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s Emgality (galcanezumab-gnlm) for migraine prevention.
-
Earlier this month, Novo Nordisk announced it was laying off 400 staffers in Denmark and China. Today, Reuters reports that the Danish company plans to lay off about 250 people in the United States.
-
Lilly's Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults
9/27/2018
Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults.1 Emgality offers a once-monthly, self-administered, subcutaneous injection.1
-
Chugai and Lilly Enter into a License Agreement for Oral GLP-1 Agonist, OWL833
9/27/2018
The agreement will bolster Lilly’s industry-leading diabetes portfolio
-
Making the jump from biotech to politics may not seem like a typical career progression. So, what is driving these executives into politics?
-
Recently, BioSpace posted a question on its website, under the heading, “We Want to Hear from You! Top Life Sciences Trends.” Let’s take a look at the five trends survey participants mentioned.
-
Eli Lilly just signed a license deal with Tokyo’s Chugai Pharmaceutical Co. for OWL833, Chugai’s oral non-peptidic GLP-1 receptor agonist. It is Phase 1-ready being evaluated for type 2 diabetes.
-
AstraZeneca announced positive results from its Phase III DECLARE-TIMI 58 cardiovascular outcomes clinical trial of Farxiga (dapagliflozin).
-
New York-based Y-mAbs Therapeutics will look at securing $96 million through an initial public offering to support development of its antibody-based therapeutic treatments for cancer.
-
Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found. The U.S. Centers for Disease Control and Prevention published a new report in the journal Alzheimer’s & Dementia projecting the disease’s likely expansion, and for the firs...
-
Following AbbVie Lawsuit, Government Scrutinizes Industry-Provided Drug Educational Support Services
9/21/2018
A federal investigation is underway into whether or not the nursing and other medical services provided by some pharmaceutical companies to doctor’s offices actually violate the law due to serving an illegal commercial service. -
According to BioPharmCatalyst, there have been (or soon will be) 58 biopharma initial public offerings (IPOs) in 2018, and there’s still more than three months to go.
-
House Rejects Senate Bill Provision to Require Disclosure of Drug Prices in Television Commercials
9/18/2018
The U.S. House of Representatives has split with the Senate over requiring pharmaceutical companies to disclose the list price of their prescription medications in television advertisements. -
The U.S. Food and Drug Administration (FDA) approved Teva Pharmaceutical Industries’ Ajovy (fremanezumab) to prevent migraine on Friday, September 16.
-
As the Morgan Stanley Global Healthcare Conference runs from September 12 through 14, numerous biopharma companies are making presentations, updating their operations and pipeline activities. Here’s a look at some of the highlights.
-
New Lilly Diabetes Center of Excellence Established at the Indiana Bioscience Research Institute
9/13/2018
New center will be a central Indiana nexus for advanced diabetes research and talent attraction